Search

Displaying results 4111 - 4120 of 7059 in total
  1. Drug

    Lecithin, soybean

    go.drugbank.com/drugs/DB14161
    Investigational

    Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk. … A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed

    Mixtures: GNC PP AA Formula
  2. Drug

    Otilimab

    go.drugbank.com/drugs/DB06303
    Investigational

    Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).

  3. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.

  4. Drug

    Potassium triiodide

    go.drugbank.com/drugs/DB14492
    Investigational

    Mixtures: CitraNatal 90 DHACategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Monlunabant

    go.drugbank.com/drugs/DB21537
    Investigational

    Monlunabant has a monoisotopic molecular weight of 590.11 Da. … Monlunabant is a small molecule drug. The usage of the INN stem '-nabant' in the name indicates that Monlunabant is a cannabinoid receptor antagonist.

  6. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  7. Drug

    Isocarboxazid

    go.drugbank.com/drugs/DB01247
    Approved

    [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    Fluorescein

    go.drugbank.com/drugs/DB00693
    ApprovedInvestigational

    A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal … It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)

    Categories: Compounds used in a research, industrial, or household settingSynonyms: D&C Yellow No. 7, D and C Yellow No. 7
  9. Drug

    Tizaterkib

    go.drugbank.com/drugs/DB21296
    Investigational

    Tizaterkib has a monoisotopic molecular weight of 494.2 Da. … Tizaterkib is a small molecule drug. The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor.

  10. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat has a monoisotopic molecular weight of 494.21 Da. … Mizacorat is a small molecule drug. The usage of the INN stem '-corat' in the name indicates that Mizacorat is a glucocorticoid receptor agonist.